Related Experiment Video
Updated: Jun 10, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland
I Vickers1, M Fitzgerald, S Murchan
1Epidemiology and Molecular Biology Unit and Irish Meningococcal and Meningitis Reference Laboratory, Children's University Hospital, Dublin, Ireland. imelda.vickers@cuh.ie
Insights
The 7-valent pneumococcal conjugate vaccine (PCV7) reduced invasive pneumococcal disease in Irish infants. Serotype 14 remained common, and a new serotype 6C was identified, impacting vaccine effectiveness.
Area of Science:
- Microbiology
- Immunology
- Public Health
Background:
- The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into Ireland's routine infant immunization program in September 2008.
- Invasive pneumococcal disease (IPD) remains a significant public health concern, particularly in young children.
Purpose of the Study:
- To determine the serotype distribution of Streptococcus pneumoniae isolates causing invasive disease in Ireland before and after PCV7 introduction.
- To assess the prevalence of the novel serotype 6C and evaluate antibiotic susceptibility patterns.
- To estimate the potential impact of PCV7 on IPD in children under two years old.
Main Methods:
- Analysis of 977 S. pneumoniae isolates from invasive disease cases during 2000-2002 and 2007-2008.
- Serotyping of isolates and specific assessment for serotype 6C.
- Determination of susceptibility to penicillin and cefotaxime for isolates from 2007-2008.
Main Results:
- Serotype 14 was the most prevalent serotype in both study periods.
- Approximately 7.7% of isolates previously identified as serotype 6A were reclassified as the newly described serotype 6C.
- PCV7's potential to prevent IPD in children under two decreased from 85% (2000-2002) to 74% (2007-2008).
- Penicillin non-susceptibility was observed in 17% of isolates in 2007-2008.
Conclusions:
- Ongoing surveillance of pneumococcal serotypes is crucial to monitor the impact of PCV7 and inform future vaccination strategies.
- The emergence of serotype 6C and shifts in serotype prevalence may affect the long-term effectiveness of current vaccines.
- The findings highlight the need for updated vaccines with broader serotype coverage to address evolving pneumococcal epidemiology.
Abstract:
The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.
Related Concept Videos
Atypical Pneumonia
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Streptococcal Pharyngitis
Bacterial Meningitis I: Introduction
Respiratory Syncytial Virus Disease

